Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Myasthenia Gravis

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Missouri-Columbia

About this trial

During this pilot study, the investigators will examine the effects of whole-body electrical muscle stimulation exercise (WB-EMS Exercise) on neuromuscular junction (NMJ) transmission and fatigability in adults with Generalized Myasthenia Gravis (gMG). The investigators will also test whether a relationship exists between NMJ transmission dysfunction and fatigability in gMG, which has long been presumed but never directly assessed. Participants will undergo clinical and electrophysiologic testing before and after the WB-EMS Exercise intervention. The WB-EMS Exercise intervention will be delivered 2 times per week for 4 weeks. Long-term follow up is optional. The hypotheses are (a) that the WB-EMS exercise will improve fatigability and NMJ transmission, and (b) that NMJ transmission dysfunction is related to fatigability.

Eligibility criteria

Qualifiers

Age 18 or older

Diagnosed with Generalized Myasthenia Gravis (gMG) via seropositive test for acetylcholine receptor (AChR) antibodies or seronegative test with clinical symptoms consistent with gMG

On stable MG therapy for at least 1 month

Ability to stand for approximately 15 minutes continuously with or without an assistive device (i.e. the length of time to stand to take a shower, complete meal preparation, wait in line at the bank, etc.)

Disqualifiers

Concurrent participation in another interventional research study

Unable to tolerate 15 minutes of continuous standing with or without an assistive device

Regular participation in strength training (2x per week or more over the past 6 months)

Score of 0 (None) on all "arm outstretched" and "leg outstretched" items of the QMG

Trial design

Treatments tested in this trial

  • Whole-body Electrical Muscle Stimulation Exercise

Treatment groups

16 Participants
are divided into 1 treatment group

Sponsors and collaborators

University of Missouri-Columbia

Lead sponsor

University of Kansas Medical Center

Collaborator